Short description
TVAX Biomedical develops cell-based immunotherapy for the treatment of cancer.
Description
TVAX Biomedical is a clinical stage development company advancing its targeted cell-based immunotherapy for the treatment of cancer. The company’s proprietary therapeutic approach offers the promise of improved clinical outcomes, low toxicity and the potential for fundamentally changing the way cancer is treated. TVAX Immunotherapy is a unique
personalized combination of cancer cell vaccination and “killer” T cell treatment. This treatment has demonstrated the potential to effectively treat numerous cancers without many of the
undesirable side effects associated with radiation and chemotherapy. A key distinction between TVAX and other cancer immunotherapy companies is that TVI uses its patented approach to combine both cancer vaccination and activated “killer” T cell treatment. While each of these separate approaches has demonstrated therapeutic potential, neither has demonstrated the efficacy to be a viable standalone treatment.
Total funding
$$121212
Sign in for full access
Location
Lenexa, Kansas, United States, North America
Founded on
January 1, 2004
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$7890 - 12340
Sign in for full access
Founders
Catherine E Lucasey, Gary Wood, Lowell Tilzer